We are live on !
Find out more
Pendal Group Portfolio holdings
AUM
$11.6B
Turnover
28.7%
1-Year Est. Return
12.87%
This Fund
S&P 500
This Quarter Est. Return
+1.65%
1 Year Est. Return
-12.87%
3 Year Est. Return
+52.75%
5 Year Est. Return
+103.82%
10 Year Est. Return
–
AUM
$12.1B
AUM Growth
+$1.2B
(+11%)
Cap. Flow
+$1.49B
Cap. Flow % of AUM
Cap. Flow %
12.26%
Top 10 Holdings %
Top 10 Hldgs %
30.95%
Holding
675
New
129
Increased
199
Reduced
220
Closed
109
Avg Time Held
1.6
years
Top 10 Avg Time Held
1.4
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioNTech
BNTX
|
+$463M |
| 2 |
Alibaba
BABA
|
+$168M |
| 3 |
UnitedHealth
UNH
|
+$142M |
| 4 |
Linde
LIN
|
+$136M |
| 5 |
Check Point Software Technologies
CHKP
|
+$129M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRAH
PRA Health Sciences
PRAH
|
+$115M |
| 2 |
Medpace
MEDP
|
+$115M |
| 3 |
Oracle
ORCL
|
+$112M |
| 4 |
MKS
MKSI
|
+$99.1M |
| 5 |
Aramark
ARMK
|
+$92.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.62% |
| 2 | Healthcare | 16.66% |
| 3 | Financials | 15.34% |
| 4 | Consumer Discretionary | 9.67% |
| 5 | Communication Services | 7.86% |
Similar funds
Pendal Group's Q3 2021 Portfolio in Review
As of Q3 2021, Pendal Group held 675 positions worth $12.1B, up 11% from $10.9B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Pendal Group deployed $1.49B of net new capital in Q3 2021, opening 129 new positions and adding to 199 existing holdings. Its largest new stake was BioNTech: 1,455,825 shares worth $397M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Medpace, an estimated $115M trimmed.
- Pendal Group's largest Q3 2021 buy was BioNTech: 1,455,825 shares worth $397M.
- Pendal Group added most to Alibaba in Q3 2021, an estimated $168M increase.
- Pendal Group's biggest Q3 2021 reduction was Medpace, cutting an estimated $115M.
- Pendal Group fully exited PRA Health Sciences in Q3 2021, selling an estimated $115M.
- Pendal Group's ten largest holdings make up 31% of its $12.1B portfolio in Q3 2021.
- Pendal Group opened 129 new positions and closed 109 in Q3 2021.
- Pendal Group's portfolio value rose 11% quarter-over-quarter to $12.1B.
Based on Pendal Group's 13F filing for Q3 2021, filed 5 Nov 2021.